These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 24522376)

  • 1. Early changes in [18F]FDG incorporation by breast cancer cells treated with trastuzumab in normoxic conditions: role of the Akt-pathway, glucose transport and HIF-1α.
    Fleming IN; Andriu A; Smith TA
    Breast Cancer Res Treat; 2014 Apr; 144(2):241-8. PubMed ID: 24522376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in [18F]Fluoro-2-deoxy-D-glucose incorporation induced by doxorubicin and anti-HER antibodies by breast cancer cells modulated by co-treatment with metformin and its effects on intracellular signalling.
    Cooper AC; Fleming IN; Phyu SM; Smith TA
    J Cancer Res Clin Oncol; 2015 Sep; 141(9):1523-32. PubMed ID: 25579456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in 2-fluoro-2-deoxy-D-glucose incorporation, hexokinase activity and lactate production by breast cancer cells responding to treatment with the anti-HER-2 antibody trastuzumab.
    Cheyne RW; Trembleau L; McLaughlin A; Smith TA
    Nucl Med Biol; 2011 Apr; 38(3):339-46. PubMed ID: 21492782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXO1A is a target for HER2-overexpressing breast tumors.
    Wu Y; Shang X; Sarkissyan M; Slamon D; Vadgama JV
    Cancer Res; 2010 Jul; 70(13):5475-85. PubMed ID: 20551062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resveratrol suppresses cancer cell glucose uptake by targeting reactive oxygen species-mediated hypoxia-inducible factor-1α activation.
    Jung KH; Lee JH; Thien Quach CH; Paik JY; Oh H; Park JW; Lee EJ; Moon SH; Lee KH
    J Nucl Med; 2013 Dec; 54(12):2161-7. PubMed ID: 24221993
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Dockx Y; Vangestel C; De Bruycker S; Van den Wyngaert T; Huizing M; Staelens S; Stroobants S
    Cancer Biother Radiopharm; 2023 Feb; 38(1):51-61. PubMed ID: 36472460
    [No Abstract]   [Full Text] [Related]  

  • 7. Hypoxia-independent overexpression of hypoxia-inducible factor 1alpha as an early change in mouse hepatocarcinogenesis.
    Tanaka H; Yamamoto M; Hashimoto N; Miyakoshi M; Tamakawa S; Yoshie M; Tokusashi Y; Yokoyama K; Yaginuma Y; Ogawa K
    Cancer Res; 2006 Dec; 66(23):11263-70. PubMed ID: 17145871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiRNA‑542‑3p downregulation promotes trastuzumab resistance in breast cancer cells via AKT activation.
    Ma T; Yang L; Zhang J
    Oncol Rep; 2015 Mar; 33(3):1215-20. PubMed ID: 25586125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
    Blancher C; Moore JW; Robertson N; Harris AL
    Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Administered Cardioprotective Drugs on Treatment Response of Breast Cancer Cells.
    Smith TA; Phyu SM; Akabuogu EU
    Anticancer Res; 2016 Jan; 36(1):87-93. PubMed ID: 26722031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro study of HIF-1 activation and VEGF release by bFGF in the T47D breast cancer cell line under normoxic conditions: involvement of PI-3K/Akt and MEK1/ERK pathways.
    Shi YH; Wang YX; Bingle L; Gong LH; Heng WJ; Li Y; Fang WG
    J Pathol; 2005 Mar; 205(4):530-6. PubMed ID: 15714461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition.
    Kelly CJ; Hussien K; Muschel RJ
    Nucl Med Biol; 2012 Oct; 39(7):986-92. PubMed ID: 22682985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting tumour response to anti-HER1 therapy using medical imaging: a literature review and in vitro study of [18F]-FDG incorporation by breast cancer cells responding to cetuximab.
    Smith TA; Cheyne RW
    Br J Biomed Sci; 2011; 68(3):158-66. PubMed ID: 21950209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice.
    McLarty K; Fasih A; Scollard DA; Done SJ; Vines DC; Green DE; Costantini DL; Reilly RM
    J Nucl Med; 2009 Nov; 50(11):1848-56. PubMed ID: 19837760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
    Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen-induced activation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor expression, and edema in the uterus are mediated by the phosphatidylinositol 3-kinase/Akt pathway.
    Kazi AA; Koos RD
    Endocrinology; 2007 May; 148(5):2363-74. PubMed ID: 17272396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of 18F-FDG accumulation in colorectal cancer cells with mutated KRAS.
    Iwamoto M; Kawada K; Nakamoto Y; Itatani Y; Inamoto S; Toda K; Kimura H; Sasazuki T; Shirasawa S; Okuyama H; Inoue M; Hasegawa S; Togashi K; Sakai Y
    J Nucl Med; 2014 Dec; 55(12):2038-44. PubMed ID: 25453050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
    Chan CT; Metz MZ; Kane SE
    Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiosensitizing effect of irisquinone on glioma through the downregulation of HIF-1α evaluated by 18F-FDG and 18F-FMISO PET/CT.
    Wang H; Zhang Y; Yu W; Zhao X; Xue Y; Xu H
    Nucl Med Commun; 2016 Jul; 37(7):705-14. PubMed ID: 26963468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.